TIC10/ONC201 (imipiridone) has been reported to have an antineoplastic effect on tumor cells by increasing TRAIL and DR5 transcription through the activation and nuclear translocation of FOXO3a, inactivating the kinases ERK and AKT [338]. Here, TNFRSF10B is linked to neoplasm.